Oncology nursing

Syantra Emerges from Stealth with AI Powered RNA-Based Immune Response Detection Liquid Biopsy Platform and Announces Rob Lozuk as CEO

Retrieved on: 
Wednesday, November 1, 2023
Survival, NHS foundation trust, Manchester University NHS Foundation Trust, Analytic, Oncology nursing, RNA, Conference, University of Manchester, AB, Doctor of Philosophy, Breast cancer, Wythenshawe Hospital, Cancer, Liquid biopsy, Pharmaceutical industry, Medical imaging

"We are thrilled to add an accomplished world-class executive to our leadership team to elevate our pivotal work in blood-based cancer detection.

Key Points: 
  • "We are thrilled to add an accomplished world-class executive to our leadership team to elevate our pivotal work in blood-based cancer detection.
  • "The existing early cancer detection liquid biopsy paradigm is not adequate, economical, or scalable.
  • Truly disruptive healthcare technologies are generational – and that's exactly what Syantra's liquid biopsy platform will become" states CEO of Syantra, Rob Lozuk, and adds, "I'm thrilled to be joining the Syantra team at this critical juncture in the liquid biopsy arena.
  • Our AI powered RNA-based liquid biopsy platform represents a revolution for the screening and detection modalities by measuring a key shift in the body's immune response that allows cancer to develop.

Tampa General Hospital Earns Region's Only Accreditation as a Center of Excellence in Minimally Invasive Gynecology

Retrieved on: 
Wednesday, October 18, 2023
TGH, Tampa General Hospital, Education, Health, Pain, Physician, Obstetrics, Center of excellence, Oncology nursing, Obstetrics and gynaecology, Certification, Accreditation, Infection, Trauma, News, Division, Bleeding, Surgeon, Risk, SRC, Partnership, Hospital, Women's Institute, U.S. News & World Report, Nursing, Patient safety, Blue Cross Blue Shield Association, Gynaecology, Newsweek

TAMPA, Fla., Oct. 18, 2023 /PRNewswire/ -- Tampa General Hospital (TGH) today announced its accreditation as a Center of Excellence in Minimally Invasive Gynecology through the Surgical Review Corporation (SRC), a nonprofit, patient safety organization that develops and administers best-in-class accreditation programs for hospitals, freestanding outpatient facilities and medical professionals throughout the world.

Key Points: 
  • TAMPA, Fla., Oct. 18, 2023 /PRNewswire/ -- Tampa General Hospital (TGH) today announced its accreditation as a Center of Excellence in Minimally Invasive Gynecology through the Surgical Review Corporation (SRC), a nonprofit, patient safety organization that develops and administers best-in-class accreditation programs for hospitals, freestanding outpatient facilities and medical professionals throughout the world.
  • As a program of the Surgical Review Corporation, the Center of Excellence in Minimally Invasive Gynecology identifies surgeons and facilities worldwide who perform minimally invasive gynecological procedures and achieve defined standards for patient safety and care quality.
  • In 2022, Tampa General Hospital received accreditation as a Center of Excellence in Robotic-Assisted Surgery from the Surgical Review Corporation.
  • Tampa General is the highest-ranked hospital in Florida and the ninth highest-ranked hospital in the United States for Obstetrics & Gynecology by U.S. News & World Report for 2023-2024 .

Evvy, Precision Women’s Health Startup focused on the Vaginal Microbiome, Announces $14M Series A

Retrieved on: 
Wednesday, September 27, 2023
Professional Services, Oncology, Start-Up, Consumer, Technology, Infectious Diseases, Artificial Intelligence, Health Technology, Baby, Maternity, Women, Biotechnology, Health, Pregnancy, Female, STI, Infection, Trichomoniasis, Gonorrhea, Discovery, Woman, Infertility, Prescription, Biomarker, Fungus, IRB, Data, Patient, Stanford University Medical Center, Preterm birth, Oncology nursing, Fertility, Chlamydia, Growth, Metagenomics, Bacteria, Research, Recurrence, System, PCR, Birth control, Nursing, Virtue

Vaginal discomfort is a leading reason that women seek healthcare advice in the US, with incredibly high misdiagnosis (>50%) and recurrence (>50%) rates.

Key Points: 
  • Vaginal discomfort is a leading reason that women seek healthcare advice in the US, with incredibly high misdiagnosis (>50%) and recurrence (>50%) rates.
  • Research has also uncovered groundbreaking links between the vaginal microbiome and infertility, STIs, preterm birth, gynecologic cancers, and more.
  • The Evvy Vaginal Health Test leverages mNGS to screen for all bacteria and fungi that have been isolated from the vaginal and urinary tract in a single swab.
  • They launched an integrative, personalized, AI-powered vaginal healthcare platform, and ran an IRB-approved study clinically validating that the platform improves the vaginal microbiome.

USMI to Debut the Canady Robotic AI Surgical System at the First Global Surgical Oncology Summit Jerusalem, Israel January 2024

Retrieved on: 
Friday, September 22, 2023
Research, Technology, Medical Devices, Clinical Trials, Biotechnology, Health, Robotics, Science, Oncology, Artificial Intelligence, Radiation, GOOGLE, Freedom, Use, Controller, CAP, Female gendering of AI technologies, Endoscopy, Recognition, Intelligence, Multimedia, Immunotherapy, Doctor of Philosophy, Scientist, SIRI, Clinical trial, Motorized, MD, System, Intel Extreme Masters, Education minister, FACS, Artificial intelligence, Patient, Oncology nursing, FDA, Recurrence, Safety, SMART, Medical device, Laparoscopy

The Canady Robotic AI Surgical System is the world’s first AI robotic system that delivers cold atmospheric plasma (CAP) which is a three-dimensional non-contact bioelectric pulse electromagnetic field.

Key Points: 
  • The Canady Robotic AI Surgical System is the world’s first AI robotic system that delivers cold atmospheric plasma (CAP) which is a three-dimensional non-contact bioelectric pulse electromagnetic field.
  • The Canady Robotic AI Surgical System will be displayed at the First Global Surgical Oncology Summit in Jerusalem, Israel (January 30 to February 2, 2024).
  • View the full release here: https://www.businesswire.com/news/home/20230922283953/en/
    Canady Robotic AI Surgical System (Photo: Business Wire)
    The Canady Robotic AI Surgical System’s key components are a Motorized Positioning Arm, Speech Recognition Canady Electrosurgical Generator known as ORLI™, Controller for CAP Devices, Robotic Assisted End Effectors which can be used in Open, Laparoscopic, Thoracoscopic, Endoscopic and Mini-invasive surgical procedures.
  • Taisen Zhuang, PhD, Chief Technology Officer stated, “The Canady Robotic AI Surgical System sets a new precedent for Robotic Cancer Surgery by combining AI Technology and CAP.

Scholarship Opportunity for Future Doctors: Dr. Scott Kamelle Scholarship Accepting Applications

Retrieved on: 
Tuesday, September 5, 2023
Aurora, Advocate Aurora Health, Knowledge, Student, Health, Patient, Oncology nursing, Personal, Management, Nursing, Medicine

MILWAUKEE, Sept. 5, 2023 /PRNewswire/ -- Dr. Scott Kamelle , an esteemed Gynecologic Oncologist and former Director of Gyn Oncology at Aurora Health Care in Milwaukee, is pleased to announce the launch of the Dr. Scott Kamelle Scholarship for Future Doctors.

Key Points: 
  • MILWAUKEE, Sept. 5, 2023 /PRNewswire/ -- Dr. Scott Kamelle , an esteemed Gynecologic Oncologist and former Director of Gyn Oncology at Aurora Health Care in Milwaukee, is pleased to announce the launch of the Dr. Scott Kamelle Scholarship for Future Doctors.
  • Dr. Kamelle, recognized for his exceptional care and dedication to improving patient outcomes, has established this scholarship to empower talented individuals pursuing a career in medicine.
  • The scholarship award, a one-time amount of $1,000, will provide financial assistance to deserving students on their educational journey.
  • The application deadline for the Dr. Scott Kamelle Scholarship for Future Doctors is January 15, 2024.

Pyxis Oncology Successfully Completes Acquisition of Apexigen

Retrieved on: 
Wednesday, August 23, 2023
P.C, Therapy, Par value, Vassar College, Pfizer, Sidley Austin, Antibody, Research and development, Development, Acquisition, Patient, Oncology nursing, CD40, Ladenburg Thalmann, Cancer, Conjugation, FACT, ADC, Wilson Sonsini Goodrich & Rosati, Antibody-drug conjugate, Cornell University, Fine chemical, Management, New York University, Philosophy

BOSTON, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS) (“Pyxis Oncology” or the “Company”), a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, today announced the successful completion of its acquisition of Apexigen, Inc. (“Apexigen”), a clinical-stage biopharmaceutical company focused on discovering and developing innovative antibody therapeutics for oncology, in an all-stock transaction valued at approximately $10.7 million. The combined company is positioned at the forefront of ADC innovation with a platform that now includes four key components: novel humanized antibody generation capabilities, an expanded library of linkers with improved stability, site specific conjugation chemistries, and optimized payloads.

Key Points: 
  • Xiaodong Yang, M.D., Ph.D., founder and former Chief Executive Officer of Apexigen, is joining the combined company as Distinguished Research Fellow.
  • With the closing of this transaction, Jakob Dupont, M.D., Executive Partner at Sofinnova Investments, was appointed as an Independent Director to the Pyxis Oncology Board of Directors.
  • “I’m pleased to join the Pyxis Oncology Board of Directors,” said Jakob Dupont.
  • Pyxis Oncology issued approximately 4.3 million shares of common stock as a result of this transaction, and immediately post-acquisition, Pyxis Oncology is expected to have 43,872,248 shares of common stock outstanding.

Eisai Delivers New Data and Highlights Continued Progress of Oncology Portfolio and Pipeline at ASCO 2023

Retrieved on: 
Wednesday, May 24, 2023
MSD, CREB-binding protein, Apoptosis, Carcinoma, Abstract, Senior, CBP, FR, Pembrolizumab, Cancer, Fallopian tube cancer, Bristol Myers Squibb, Research, Lung cancer, Trial of the century, ASCO, LEAP, Endometrial cancer, American Society of Clinical Oncology, Patient, Physician, Sorafenib, Oncology nursing, Annual general meeting, ADC, Merck, Poster, Merck & Co., FDA, Survival analysis, Ovarian cancer, Society, HCC, Safety, Nivolumab, Pharmaceutical industry, Eisai

Eisai entered into a joint development agreement with BlissBio for BB-1701 with option rights for a strategic collaboration in April 2023.

Key Points: 
  • Eisai entered into a joint development agreement with BlissBio for BB-1701 with option rights for a strategic collaboration in April 2023.
  • A Phase 1/2 clinical study of BB-1701 in the U.S. and China for HER2-expressing solid tumors is currently underway.
  • There is no guarantee that any investigational compounds or investigational uses of FDA-approved products will successfully complete clinical development or gain FDA approval.
  • Eisai and Merck are studying the LENVIMA plus KEYTRUDA combination through the LEAP (LEnvatinib And Pembrolizumab) clinical program in various tumor types across more than multiple clinical trials.

Statement by Dr. Arnold Baskies on WHO Aspartame Reports

Retrieved on: 
Friday, July 14, 2023
Human, Food, JECFA, Coalition, Agriculture, Food safety, Multimedia, Acceptable daily intake, National Cancer Institute, Risk, National Board of Trial Advocacy, ADI, American Cancer Society, Oncology nursing, WHO, FDA, NCI, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Safety, Dietary supplement

WASHINGTON, July 13, 2023 /PRNewswire/ -- Dr. Arnold Baskies, past Chairman of the National Board of Directors of the American Cancer Society, National Cancer Institute (NCI) Fellowship-Trained Surgical Oncologist, and a member of the Coalition for Safe Food and Beverage Choices Expert Advisory Committee released the following statement after the WHO Joint Expert Committee on Food Additives' (JECFA) review of aspartame: 

Key Points: 
  • JECFA is the authoritative international agency when it comes to food safety.
  • The FDA relies on JECFA's assessments as part of its process to determine not only what is safe to consume, but also what quantity.
  • The American people should have confidence in their food and beverage choices because JECFA is the WHO agency that measures risk to humans from ingredients."
  • If there was any cause for concern, they would have adjusted the current Acceptable Daily Intake (ADI)."

Society for Immunotherapy of Cancer Publishes Clinical Practice Guideline on Immunotherapy for the Treatment of Gynecologic Cancer

Retrieved on: 
Thursday, June 15, 2023
ICIS, MMR, Society, Education, Society for Immunotherapy of Cancer, CPG, FACP, Survival, SITC, Immunotherapy, Doctor of Philosophy, Science, Journal, Patient, Manuscript, Guideline, Oncology nursing, Health, Caregiver, Dentistry, Medical device, Cancer, JITC, MD

MILWAUKEE, June 15, 2023 /PRNewswire-PRWeb/ -- The Society for Immunotherapy of Cancer (SITC), the world's leading member-driven organization dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy, has published the first clinical practice guideline (CPG) focused on immunotherapy for the treatment of gynecologic cancer.

Key Points: 
  • The Society for Immunotherapy of Cancer (SITC), the world's leading member-driven organization dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy, has published the first clinical practice guideline (CPG) focused on immunotherapy for the treatment of gynecologic cancer.
  • MILWAUKEE, June 15, 2023 /PRNewswire-PRWeb/ -- The Society for Immunotherapy of Cancer (SITC), the world's leading member-driven organization dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy, has published the first clinical practice guideline (CPG) focused on immunotherapy for the treatment of gynecologic cancer.
  • The new manuscript, " Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancers ", was published in the Journal of ImmunoTherapy of Cancer (JITC), SITC's peer-reviewed online journal, and it will be available in SITC's mobile guidelines app.
  • "Immune checkpoint inhibitors have demonstrated strong activity in cervical and endometrial cancer," said Mary (Nora) L. Disis, MD, FACP, co-Chair of the SITC Gynecologic Cancer Clinical Practice Guideline Expert Panel.

Intensity Therapeutics Reports INT230-6 Can Cause Immune Priming in Historically Quiescent Breast Cancers

Retrieved on: 
Tuesday, June 6, 2023
Injection, The Ottawa Hospital, Intensity, Cell death, University, Macrophage, Necrosis, Breast, Cancer, Woman, NK, Ontario Institute for Cancer Research, Part, ASCO, Publication, American Society of Clinical Oncology, Mastectomy, Patient, Immune system, Annual general meeting, Surgeon, Diagnosis, Neoplasm, CD4, Oncology nursing, Therapy, Recurrence, B cell, Society, Breast cancer, Disease, Vaccine, Medical imaging, Pharmaceutical industry

WESTPORT, Conn., June 6, 2023 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity"), a clinical-stage biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral (IT) cancer therapies designed to kill tumors and increase immune system recognition of cancers, today announced that data from its INVINCIBLE study was presented on June 4, at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago and virtually from June 2-6, 2023.

Key Points: 
  • The study is evaluating clinical and biological effects in patients with early-stage operable breast cancer.
  • The study presented new immune and gene activation related results as well as data demonstrating efficacy and tolerability of INT230-6.
  • Abstract Title: A phase 2 randomized window of opportunity trial evaluating cytotoxic and immunomodulatory effects of intratumoral INT230-6 in early stage breast cancer: The INVINCIBLE Trial.
  • "For the majority of breast cancer patients, the typical waiting period of 2-6 weeks from diagnosis to surgery is a very fearful time.